• 揚(yáng)州大學(xué)附屬泰興醫(yī)院腎內(nèi)科（江蘇泰興，225400）;

【摘要】　目的　 探討瑞舒伐他汀對慢性腎病患者抗炎療效。　方法　 選取2009年11月-2010年12月90例慢性腎病患者，隨機(jī)分為A、B兩組，A組50例，給予瑞舒伐他汀鈣10 mg/d；B組40例，給予阿托伐他汀鈣10 mg/d，兩組患者的年齡和性別相匹配。分別測定其治療前及治療后12周時血白細(xì)胞、高敏反應(yīng)蛋白、纖維蛋白原、白介素-6、腫瘤壞死因子-α。　結(jié)果　 兩組治療前各炎癥指標(biāo)水平差異無統(tǒng)計學(xué)意義（P gt;0.05）。與治療前相比，兩組患者治療12周后炎癥指標(biāo)水平均較前明顯下降（P lt;0.01），瑞舒伐他汀鈣組比阿托伐他汀鈣組炎癥指標(biāo)下降更為明顯。　結(jié)論　 瑞舒伐他汀可有效改善慢性腎病患者的炎癥反應(yīng)。
【Abstract】　Objective　 To explore the anti-inflammatory effect of rosuvastatin on chronic kidney disease (CKD) patients. 　Methods　 Ninety CKD patients treated in our hospital between November 2009 and December 2010 were randomly divided into two groups. One group was given rosuvastatin calcium 10 mg/d, which the other group was given atorvastatin calcium 10 mg/d. The two groups matched in terms of age and gender. We determined blood leukocyte (WBC), high sensitivity reactive protein (hs-CRP), fibrinogen (FIG), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) of the patients before and after treatment for 12 weeks.　Results　 The inflammatory marker levels of both groups before treatment had no significant difference (P gt;0.05). The inflammatory marker levels of two groups after treatment for 12 weeks were significantly decreased compared with the levels before treatment (P lt;0.01), and rosuvastatin calcium group decreased more apparently than atorvastatin calcium group.　Conclusion　 Rosuvastatin can improve the anti-inflammatory response in CKD patients.

引用本文： 王國華,章旭,曹娟,李海濤,印荻,周長菊,許琴,丁浩,趙彩霞. 瑞舒伐他汀對慢性腎病患者抗炎作用的臨床觀察. 華西醫(yī)學(xué), 2011, 26(9): 1287-1289. doi: 復(fù)制

1. 　Wanner C, Zimmermann J, Schwedler S, et al. Inflammation and cardiovascular risk in dialysis patients[J]. Kidney Int, 2002, 18(8): 1452-1455.
2. 　Dimitrow PP, Jawień M. Anti-inflammatory effect of atorvastatin in patients with aortic sclerosis or mild aortic stenosis independent of hypercholesterolemia[J]. Pharmacological Rep, 2010, 62(6): 1250-1254.
3. 　März W, Genser B, Drechsler C, et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis[J]. Clin J Am Soc Nephrol, 2011, 6(6): 1316-1325.
4. 　Her AY, Kim JY, Kang SM, et al. Effects of atorvastatin 20 mg,rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism[J]. J Cardiovasc Pharmacol Ther, 2010, 15(2): 167-174.
5. 　Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency[J]. Circulation, 2003, 107(1): 87-92.
6. 　Recio-mayoral A, Banerjee D, Streather C, et al. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease:a cross-sectional study of predialysis, dialysis and kidney-transplantation patients[J]. Atherosclerosis, 2011, 216(2): 446-451.
7. 　Zyga S, Christopoulou G, Malliarou M. Malnutrition-inflammation-atherosclerosis syndrome in patients with end-stage renal disease[J]. J Ren Care, 2011, 37(1): 12-15.
8. 　Michel C, Giuseppe L, Martina M, et al. Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis[J]. Nephrol Dial Transplant, 2008, 23(9): 2879-2883.
9. 　Ross R. Atrheroselerosis-an inflammatory disease[J]. N Engl J Med, 1999, 340(2): 115-126.
10. 　王海燕. 腎臟病學(xué)[M]. 3版. 北京: 人民衛(wèi)生出版社, 2008: 1886-1892.
11. 　Goldsmith D, Covic AC. Jupiter or Aurora? Micro-inflammation and dyslipidaemia: twin targets for statin therapy in CKD[J]. Int Urol Nephrol, 2010, 42(1): 133-136.
12. 　李秋榮, 王勤, 曲環(huán), 等. 瑞舒伐他汀對血脂正常的2型糖尿病患者血清高敏C反應(yīng)蛋白的作用[J]. 中華高血壓雜志, 2011, 19(3): 280-282.
13. 　嚴(yán)慶場, 吳廣華. 瑞舒伐他汀對急性冠脈綜合征患者CRP, LOX-1的影響[J].中華全科醫(yī)學(xué), 2011, 9(4): 581-632.
14. 　Burmeister JE, Miltersteiner DR, Campos BM. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein[J]. J Nephrol, 2009, 22(1): 83-89.
15. 　Verma A, Ranganna KM, Reddy RS, et al. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease[J]. Am J Cardiol, 2005, 96(9): 1290-1292.
16. 　Gómez-García A, Martínez Torres G, Ortega-Pierres LE, et al. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia[J]. Rev Esp Cardiol, 2007, 60(12): 1242-1249.
17. 　Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. N Engl J Med, 2008, 359(21): 2195-2207.
18. 　Qu HY, Xiao YW, Jiang GH, et al. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia[J]. Pharm Res, 2009, 26(4): 958-964.
  1. 1. 　Wanner C, Zimmermann J, Schwedler S, et al. Inflammation and cardiovascular risk in dialysis patients[J]. Kidney Int, 2002, 18(8): 1452-1455.
  2. 2. 　Dimitrow PP, Jawień M. Anti-inflammatory effect of atorvastatin in patients with aortic sclerosis or mild aortic stenosis independent of hypercholesterolemia[J]. Pharmacological Rep, 2010, 62(6): 1250-1254.
  3. 3. 　März W, Genser B, Drechsler C, et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis[J]. Clin J Am Soc Nephrol, 2011, 6(6): 1316-1325.
  4. 4. 　Her AY, Kim JY, Kang SM, et al. Effects of atorvastatin 20 mg,rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism[J]. J Cardiovasc Pharmacol Ther, 2010, 15(2): 167-174.
  5. 5. 　Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency[J]. Circulation, 2003, 107(1): 87-92.
  6. 6. 　Recio-mayoral A, Banerjee D, Streather C, et al. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease:a cross-sectional study of predialysis, dialysis and kidney-transplantation patients[J]. Atherosclerosis, 2011, 216(2): 446-451.
  7. 7. 　Zyga S, Christopoulou G, Malliarou M. Malnutrition-inflammation-atherosclerosis syndrome in patients with end-stage renal disease[J]. J Ren Care, 2011, 37(1): 12-15.
  8. 8. 　Michel C, Giuseppe L, Martina M, et al. Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis[J]. Nephrol Dial Transplant, 2008, 23(9): 2879-2883.
  9. 9. 　Ross R. Atrheroselerosis-an inflammatory disease[J]. N Engl J Med, 1999, 340(2): 115-126.
  10. 10. 　王海燕. 腎臟病學(xué)[M]. 3版. 北京: 人民衛(wèi)生出版社, 2008: 1886-1892.
  11. 11. 　Goldsmith D, Covic AC. Jupiter or Aurora? Micro-inflammation and dyslipidaemia: twin targets for statin therapy in CKD[J]. Int Urol Nephrol, 2010, 42(1): 133-136.
  12. 12. 　李秋榮, 王勤, 曲環(huán), 等. 瑞舒伐他汀對血脂正常的2型糖尿病患者血清高敏C反應(yīng)蛋白的作用[J]. 中華高血壓雜志, 2011, 19(3): 280-282.
  13. 13. 　嚴(yán)慶場, 吳廣華. 瑞舒伐他汀對急性冠脈綜合征患者CRP, LOX-1的影響[J].中華全科醫(yī)學(xué), 2011, 9(4): 581-632.
  14. 14. 　Burmeister JE, Miltersteiner DR, Campos BM. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein[J]. J Nephrol, 2009, 22(1): 83-89.
  15. 15. 　Verma A, Ranganna KM, Reddy RS, et al. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease[J]. Am J Cardiol, 2005, 96(9): 1290-1292.
  16. 16. 　Gómez-García A, Martínez Torres G, Ortega-Pierres LE, et al. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia[J]. Rev Esp Cardiol, 2007, 60(12): 1242-1249.
  17. 17. 　Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. N Engl J Med, 2008, 359(21): 2195-2207.
  18. 18. 　Qu HY, Xiao YW, Jiang GH, et al. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia[J]. Pharm Res, 2009, 26(4): 958-964.